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system, just as it is not present in the Resource-based
Relative Value Scale.
I am sorry that the authors did not have a comment
about the bogus nature of this method of determining
reimbursement. The method is actually a cost-contain-
ment mechanism that is being used arbitrarily by the gov-
ernment to control reimbursement to physicians. I think
the authors do the practice of medicine and the public a
disservice by tacitly agreeing with this concept by their
thorough investigation. Stepping outside of the box and
commenting on the fundamental validity of this system
would have been extremely useful for everyone.
James P. Weaver, MD
Central Carolina Cardiovascular and Thoracic Surgical Associates,
P.A.
Durham, N.C.
24/41/90593
Reply
To the Editors:
Dr. Weaver’s letter is interesting and provocative. He
suggests that participation in the Resource-based Relative
Value Scale 5-year review implies validation of process, and
he concludes that we have done the practice of medicine
and the public a disservice through tacit approval. Indeed,
we did not use our manuscript to condemn process.
Perhaps that was a missed opportunity, but in fact, by
working within the admittedly flawed process, vascular
surgeons convinced the Specialty Society Relative Value
Update Committee and the Health Care Financing
Administration (HCFA) that our work values desperately
deserved upward adjustment. From that perspective, the
greater error may have been submission of just a few
rather than all 200 vascular surgery codes for reconsidera-
tion during the 5-year review.
Nevertheless, validity of process is terribly important,
and value to the consumer is not an identifiable compo-
nent of the Resource-based Relative Value Scale. Both
concepts deserve scrutiny in light of the upcoming
resource-based practice expense program, which is due to
begin January 1, 1999. The HCFA will shift billions of
dollars in annual payments from procedural to cognitive
disciplines on the basis of faulty data, dubious accounting
methods, and a firm but entirely unsubstantiated convic-
tion that after 6 years of payment reductions, surgeons are
still overpaid by Medicare. In this, Dr. Weaver’s claim of
bogus methodology is most correct. The Government
Relations Committee of the Joint Council sent two
detailed and highly critical comment letters to the HCFA
in 1997 decrying invalidity of the practice expense relative
value process. (Copies are available from the Society
offices in Manchester, Mass.) In addition, our position has
been voiced at several HCFA meetings on practice
expense during the past 24 months. Regardless, the
HCFA’s apparent driver remains manipulation of process
to achieve a revenue-shifting goal rather than fairness in
distribution of a limited pot of Medicare funds.
In May 1998, the proposed Medicare Fee Schedule
for 1999 will be published in the Federal Register. Every
surgeon will have 60 days to tell the HCFA their thoughts
on process validity and bottom-line result. Those surgeons
who believe the upcoming reduction in practice expense
revenue will threaten their ability to stay in business
should share those concerns with their appropriate con-
gressional delegates. The news may surprise them.
So, where is the value to the consumer in all of this?
Why has the consumer remained silent? Will shrinking
Medicare reimbursement create a price-point below which
access to high-quality vascular surgical services will disap-
pear? Will consumers actually know when that happens?
Resource-based practice expense may offer an opportuni-
ty to test Dr. Weaver’s hypothesis that value to the con-
sumer is a functional paradigm in American medicine.
Robert M. Zwolak, MD, PhD
Dartmouth-Hitchcock Medical Center
Lebanon, N.H.
24/41/90592
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